Surveyor Capital, a fundamental equities strategy of Citadel, focuses on deep fundamental research across diverse sectors including Consumer, Financials, Healthcare, Industrials, Energy & Natural Resources, and Technology, Media & Telecom. Their strategy involves developing independent views on companies, leveraging a market-neutral risk framework to minimize broad market exposures, and also acting as a seeding platform for long/short equity hedge fund managers.
93% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (41% of deals). Average disclosed round size is $122.8M (across 29 rounds with reported amounts).
Portfolio
29
Fund Size
—
Top Stage
Series B
Last 12 Mo
4
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
29 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSoley Therapeutics | Series C | $200M | Jan 2026 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
| SSolve Therapeutics, Inc. | Series D | $120M | Nov 2025 |
 Adcytherix | Series A | $105M | Oct 2025 |
| DDBV Technologies S.A. | Unknown | $306.9M | Mar 2025 |
 Arbor Biotechnologies Inc | Series C | $73.9M | Mar 2025 |
 35Pharma Inc. | Series C | $53M | Nov 2024 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Outpace Bio | Series B | $144M | Aug 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
| CCompass Pathways | Unknown | $285M | Aug 2023 |
 Quanta Therapeutics | Series D | $50.7M | May 2023 |
 Plexium, Inc. | Growth | $102M | Feb 2022 |
 Arkuda Therapeutics | Series B | $64M | Feb 2022 |
 ImmPACT Bio USA, Inc. | Series B | $111M | Jan 2022 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
| GGennao Bio | Series A | $40M | May 2021 |
 DTx Pharma | Series B | $100M | Mar 2021 |
 Vera Therapeutics | Series C | $80M | Jan 2021 |
 Neuron23 | Series B | $113.5M | Dec 2020 |
 Enliven Therapeutics | Series B | $85M | Dec 2020 |
| BBioShin Limited | Series A | $60M | Sep 2020 |
Page 1 of 2
Top Co-Investors
Logos Capital10 shared
RA Capital Management9 shared
Janus Henderson Investors7 shared
Cormorant Asset Management5 shared
Pivotal bioVenture Partners5 shared
Sofinnova Partners4 shared
Atlas Venture4 shared
Deep Track Capital4 shared
Vivo Capital4 shared
Alexandria Venture Investments4 shared
OrbiMed3 shared
Pfizer Ventures3 shared
Ally Bridge Group3 shared
ARCH Venture Partners3 shared
Samsara BioCapital3 shared
Rock Springs Capital3 shared
Redmile Group3 shared
Avidity Partners2 shared
Longitude Capital2 shared
Eli Lilly and Company2 shared
Last updated: 4 May 2026